Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8151-8160 Newer>

The Motley Fool December 19, 2011	4 Biotechs Dominating the Week Our analysts discuss the fortunes of health care stocks and their critical trial results.
The Motley Fool December 19, 2011 Seth Jayson	Cooper Companies Crushes Estimates For the quarter ended Oct. 31, Cooper Companies met expectations on revenues and crushed them on EPS. Gross margins increased, operating margins contracted, and net margins widened.
The Motley Fool December 17, 2011 Stephanie Baum	Kensey Nash Opts for Mediation in Royalties Dispute With St. Jude Kensey Nash withdraws guidance; shares plummet.
The Motley Fool December 16, 2011 Brian Orelli	Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function.
The Motley Fool December 16, 2011 Selena Maranjian	Make Money in Strong Pharmaceutical Stocks the Easy Way If you expect the pharmaceutical industry to thrive as our population grows, ages, and develops medical conditions, the PowerShares Dynamic Pharmaceuticals ETF could save you a lot of trouble.
The Motley Fool December 16, 2011 Rebecca Lipman	Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most The "smart money" thinks these drug companies have more upside than downside.
The Motley Fool December 16, 2011 Brian Orelli	Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value.
The Motley Fool December 16, 2011 Brian Orelli	Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech.
The Motley Fool December 15, 2011 Brian Orelli	BioSante Shares Crushed by Placebo Effect BioSante's LibiGel efficacy is not deemed statistically significant.
The Motley Fool December 15, 2011 David Williamson	1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today.
<Older 8151-8160 Newer> Return to current articles.